151 related articles for article (PubMed ID: 36326895)
1. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
Ono R; Nishimura K; Takahashi H; Hori Y; Fukushima K; Kobayashi Y
Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):323-336. PubMed ID: 36326895
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
[TBL] [Abstract][Full Text] [Related]
3. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
[TBL] [Abstract][Full Text] [Related]
4. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.
Ikeda K; Tachibana H
J Arrhythm; 2016 Feb; 32(1):42-50. PubMed ID: 26949430
[TBL] [Abstract][Full Text] [Related]
5. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
[TBL] [Abstract][Full Text] [Related]
7. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
Liu Z; Zhang H; Xie Q; Mu G; Zhou S; Wang Z; Wang Z; Jiang J; Xiang Q; Cui Y
Clin Ther; 2020 Oct; 42(10):2066-2081.e9. PubMed ID: 32900534
[TBL] [Abstract][Full Text] [Related]
8. Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
Suzuki S; Morishima Y; Takita A; Yagi N; Otsuka T; Arita T; Yamashita T
Heart Vessels; 2019 Dec; 34(12):2011-2020. PubMed ID: 31123819
[TBL] [Abstract][Full Text] [Related]
9. Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation.
Ono R; Nishimura K; Takahashi H; Hori Y; Fukushima K; Kobayashi Y
Drugs R D; 2022 Dec; 22(4):281-288. PubMed ID: 36104542
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.
Kumano O; Suzuki S; Yamazaki M; An Y; Yasaka M; Ieko M;
Int J Lab Hematol; 2023 Feb; 45(1):119-125. PubMed ID: 36114152
[TBL] [Abstract][Full Text] [Related]
12. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
14. Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.
Osanai H; Ajioka M; Masutomi T; Kuwayama T; Ishihama S; Sakamato Y; Otaka N; Sakaguchi T; Inoue Y; Kanbara T; Nakashima Y; Asano H; Sakai K
Circ J; 2015; 79(12):2584-90. PubMed ID: 26439323
[TBL] [Abstract][Full Text] [Related]
15. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function.
Testa S; Dellanoce C; Paoletti O; Cancellieri E; Morandini R; Tala M; Zambelli S; Legnani C
Thromb Res; 2019 Mar; 175():61-67. PubMed ID: 30721819
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban.
Sakaguchi T; Osanai H; Murase Y; Ishii H; Nakashima Y; Asano H; Suzuki S; Takefuji M; Inden Y; Sakai K; Murohara T; Ajioka M
J Cardiol; 2017 Sep; 70(3):244-249. PubMed ID: 28017463
[TBL] [Abstract][Full Text] [Related]
18. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
[TBL] [Abstract][Full Text] [Related]
19. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
[TBL] [Abstract][Full Text] [Related]
20. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
